More can, and should, be done to improve the transparency and integrity of how local governments help fund Medicaid, but it’s ...

Fortunately, the Food and Drug Administration (FDA) recently decided to remove Risk Evaluation and Mitigation Strategy (REMS) ...

William D. J. Roberts, MBA, MSc is a Commonwealth Fund Harkness Fellow and a Research Fellow at both the Harvard T.H. Chan School of Public Health and Brown ...

CMMI has spent more than a decade learning which organizations consistently deliver high-value care. The next step is to let ...

The surge in vaccine litigation is not simply a post-pandemic, temporary issue. It is a deeper erosion of the legal principles that have long supported public health authority.

CMS and states should look beyond simply expanding disclosure and improving standardization to also elevate antitrust safeguards.

The emergence of Lilly’s bundling strategy for Zepbound and Taltz reflects the unregulated state of patient assistance programs in the commercial market and the need for Congressional intervention.

In postacute care, we have built a quality architecture that treats falls as actionable events and functional decline as expected aging. The resulting safety-without-recovery trade-off is not a ...

Women who are pregnant or recently gave birth are significantly more likely to be killed by an intimate partner than nonpregnant, nonpostpartum women of reproductive age, implicating the risk of fatal ...

While this litigation is unlikely to be resolved in the near term, such lawsuits can be powerful tools in exposing anti-competitive behavior and encouraging transparency and competition in ways that ...

Isaac Kabrick is a fellow with the Center for Health Policy and the Law at the O’Neill Institute. The son of two nurses, Kabrick is interested in connecting peopl ...

As with so many core functions of public health, the future success of vaccine promotion research depends on the support of every institution: government, universities, and industry alike.